Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade + dexamethasone + fotemustine in relapsed/refractory multiple myeloma
2009-011838-10Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Apr 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, dexamethasone and fotemustine in multiple myeloma (MM), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Number of patients with toxicity at maximum dose. Started Apr 2009; status: completed.
02
Drugs
bortezomibdexamethasonefotemustine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-011838-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011838-10.